Literature DB >> 8192727

Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan.

M Tomimatsu1, N Ishiguro, M Taniai, H Okuda, A Saito, H Obata, M Yamamoto, K Takasaki, M Nakano.   

Abstract

BACKGROUND: In hepatocellular carcinoma (HCC), a high prevalence of hepatitis C virus antibody (anti-HCV) has been reported, indicating that it may be an important etiologic factor in the pathogenesis of HCC. In this study, the authors investigated the prevalence of anti-HCV in HCC patients, as well as the same prevalence in patients with cholangiocarcinoma (CC) and combined hepatocellular-cholangiocarcinoma (combined HCC-CC), to study the clinicopathologic features of anti-HCV-positive cases.
METHODS: The authors examined 141 patients with primary liver cancer who were pathologically diagnosed as having HCC (121 cases), CC (13 cases), or combined HCC-CC (7 cases). Hepatitis B surface antigen (HBsAg) and anti-HCV were measured in these patients.
RESULTS: Of 121 HCC cases, 85 (70.3%) were found to be anti-HCV positive, 16 (13.2%) were HBsAg positive, and 5 (4.1%) were both anti-HCV and HBsAg positive. In 13 cases with CC and in 7 with combined HCC-CC examined, 4 (30.8%) and 5 (71.4%), respectively, were anti-HCV positive.
CONCLUSIONS: The anti-HCV-positive rate was high in combined HCC-CC as well as in HCC. These three types of primary liver cancer, which were anti-HCV positive, shared two common features: male dominance and high incidences of complication with liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8192727     DOI: 10.1002/1097-0142(19930801)72:3<683::aid-cncr2820720310>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Identification of a hepatic factor capable of supporting hepatitis C virus replication in a nonpermissive cell line.

Authors:  C T Yeh; H Y Lai; T C Chen; C M Chu; Y F Liaw
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  A case of intrahepatic cholangiocarcinoma detected after successful interferon therapy for chronic hepatitis C.

Authors:  Hiroji Shinkawa; Seikan Hai; Hiromu Tanaka; Shigekazu Takemura; Kazuki Ohba; Takahiro Uenishi; Shintaro Kodai; Yorihisa Urata; Kazuhisa Kaneda; Masayuki Sakae; Kenichi Wakasa; Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2009-12-03

Review 3.  Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis.

Authors:  Shun-ichi Ariizumi; Masakazu Yamamoto
Journal:  Surg Today       Date:  2014-09-25       Impact factor: 2.549

Review 4.  Surgical outcomes of intrahepatic cholangiocarcinoma.

Authors:  Masakazu Yamamoto; Shun-ichi Ariizumi
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

5.  Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Authors:  Won-Suk Lee; Kwang-Woong Lee; Jin-Seok Heo; Sung-Ju Kim; Seong-Ho Choi; Yong-Il Kim; Jae-Won Joh
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

6.  Hepatitis B or C virus serology as a prognostic factor in patients with hepatocellular carcinoma.

Authors:  S A Ahmad; M M Bilimoria; X Wang; F Izzo; P Delrio; P Marra; T P Baker; G A Porter; L M Ellis; J N Vauthey; S Dhamotharan; S A Curley
Journal:  J Gastrointest Surg       Date:  2001 Sep-Oct       Impact factor: 3.452

7.  Synchronous development of HCC and CCC in the same subsegment of the liver in a patient with type C liver cirrhosis.

Authors:  Takuya Watanabe; Jun Sakata; Takashi Ishikawa; Yoshio Shirai; Takeyasu Suda; Haruka Hirono; Katsuhiko Hasegawa; Kenji Soga; Koichi Shibasaki; Yukifumi Saito; Hajime Umezu
Journal:  World J Hepatol       Date:  2009-10-31

8.  A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma.

Authors:  Shaffer R S Mok; Sachin Mohan; Navjot Grewal; Adam B Elfant; Thomas A Judge
Journal:  J Gastrointest Oncol       Date:  2016-08

Review 9.  Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.

Authors:  An-Qiang Wang; Yong-Chang Zheng; Juan Du; Cheng-Pei Zhu; Han-Chun Huang; Shan-Shan Wang; Liang-Cai Wu; Xue-Shuai Wan; Hao-Hai Zhang; Ruo-Yu Miao; Xin-Ting Sang; Hai-Tao Zhao
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

10.  Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer.

Authors:  T Uenishi; S Kubo; K Hirohashi; H Tanaka; T Shuto; T Yamamoto; S Nishiguchi
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.